Related Experiment Video
Updated: Aug 14, 2025
Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model
Published on: May 6, 2020
Osteoarthritis today: Lost in translation?
Sarah Kennedy1, Jeyanesh R S Tambiah1, Nancy E Lane2
1Biosplice Therapeutics Inc., San Diego, CA, United States.
Abstract:
Osteoarthritis (OA) is a highly prevalent joint disease that is associated with pain, loss of function, and high direct and indirect economic costs. The current therapeutic options are inadequate, providing only a moderate symptom relief without the possibility of disease modification. While treatment options and personalized medicines are increasing for many complex diseases, OA drug development has been impeded by the advanced state of disease at the time of diagnosis and intervention, heterogeneity in both symptoms and rates of progression, and a lack of validated biomarkers and relevant outcome measures. This review article summarizes the OA landscape, including therapies in development as potential OA treatments, potential biomarkers undergoing evaluation by the US Food and Drug Administration, and a summary of current OA treatment guidelines, with a particular focus on the knee OA.
Insights
Osteoarthritis (OA) treatments offer limited relief and cannot modify the disease. New drug development faces challenges due to late diagnosis and disease variability, necessitating better biomarkers and outcome measures for effective knee OA management.
Area of Science:
- Orthopedics
- Rheumatology
- Pharmacology
Background:
- Osteoarthritis (OA) is a prevalent joint disease causing pain, functional loss, and significant economic burden.
- Current OA therapies provide only moderate symptom relief and lack disease-modifying capabilities.
- Drug development for OA is hindered by late diagnosis, disease heterogeneity, and a lack of validated biomarkers.
Purpose of the Study:
- To review the current landscape of osteoarthritis (OA).
- To summarize emerging therapies and potential biomarkers for OA treatment.
- To outline current OA treatment guidelines, focusing on knee OA.
Main Methods:
- Literature review of OA therapies in development.
- Analysis of potential biomarkers undergoing evaluation.
- Summary of existing OA treatment guidelines.
Main Results:
- Identified limitations in current OA therapeutic options.
- Highlighted challenges in OA drug development, including heterogeneity and biomarker scarcity.
- Presented an overview of ongoing research and established treatment protocols for knee OA.
Conclusions:
- There is a critical need for disease-modifying OA treatments.
- Advancements in biomarker identification and outcome measures are crucial for future OA drug development.
- Current guidelines emphasize symptom management, but novel approaches are required for effective OA intervention.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:31Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...